Japanese market could help bolster flagging Evusheld revenues

12 September 2022
astrazeneca_big

A research note from GlobalData suggests that AstraZeneca (LSE: AZN), the British pharma major responsible for the coronavirus vaccine Vaxzevria and antibody therapy Evusheld (tixagevimab), can expect positive uptake for the latter in Japan.

The long-acting antibody combination has been approved by Japan’s Ministry of Health, Labor and Welfare (MHLW) for the prevention and treatment of COVID-19.

The market could prove important to generating momentum in the near-term, with global sales of Evusheld having dropped in the second quarter, coming it at $445 million, down from $469 million at the start of the year.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology